TPST NASDAQ
Tempest Therapeutics, Inc.
1W: -13.4%
1M: -2.2%
3M: -24.6%
YTD: -38.6%
1Y: -73.0%
3Y: -93.1%
5Y: -87.8%
$1.86
+0.05 (+2.76%)
Weekly Expected Move ±14.2%
$1
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.5M
Congress—
ETF Holdings—
Key Statistics
Market Cap$8.3M
52W Range1.5-12.23
Volume58,445
Avg Volume205,382
Beta-1.69
Dividend—
Analyst Ratings
Company Info
CEOMatthew Angel
Employees24
SectorHealthcare
IndustryBiotechnology
IPO Date2012-11-12
Websitetempesttx.com
7000 Shoreline Court
Brisbane, CA 94080
US
Brisbane, CA 94080
US
415 798 8589
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Latest News
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
12 Health Care Stocks Moving In Friday's Intraday Session
New Strong Buy Stocks for April 10th
HC Wainwright Issues Optimistic Estimate for TPST Earnings
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Trojanowski Justin | A-Award | 22,000 | $1.64 | 2026-03-31 |
| Maestas Nicholas | A-Award | 140,000 | $1.64 | 2026-03-31 |
| Angel Matthew | P-Purchase | 231,482 | $2.16 | 2026-03-24 |
| Angel Matthew | A-Award | 269,621 | $2.38 | 2026-02-04 |
| Angel Matthew | 0 | — | 2026-02-03 |